Premorbid angiotensin converting enzyme inhibitors or angiotensin II receptor blockers in patients with sepsis
Premorbid angiotensin converting enzyme inhibitors or angiotensin II receptor blockers in patients with sepsis
复制标题
DOI：
10.1016/j.ajem.2022.10.006
复制
发表时间：
2022-10-19
影响因子：
3.6
通讯作者：
Sato, Ryota
中科院分区：
文献类型：
--
作者：
Hasegawa, Daisuke;Lee, Young Im;Sato, Ryota
目的：本研究的目的是进行系统评价和荟萃分析，探讨病前使用血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂（ACEI/ARB）对脓毒症患者短期死亡率的影响。数据来源：根据以下资格标准检索 Embase、Cochrane 对照试验中央注册库和 MEDLINE 的研究。该方案在 PROSPERO 注册 (CRD42022309129)。 研究选择：资格标准如下：(1) 随机对照试验、队列研究、横断面研究，(2) 年龄 >= 16 岁的脓毒症患者，(3) 病前接受或未接受 ACEI/ARB。 数据提取：提取患者和研究特征和结果。所有分析均使用随机效应模型进行。主要结局是短期死亡率，定义为
Objective: The aim of this study was to conduct a systematic review and meta-analysis to investigate the effect of the premorbid use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ACEI/ARB) on short-term mortality in patients with sepsis. Data sources: Embase, the Cochrane Central Register of Controlled Trials, and MEDLINE were searched for studies based on the below eligibility criteria. The protocol was registered at the PROSPERO (CRD42022309129).Study selection: Eligibility criteria were as follows: (1) randomized controlled trials, cohort studies, cross-sectional studies, (2) patients with sepsis aged >= 16 years, and (3) received premorbid ACEI/ARB, or not.Data extraction: The patient and study characteristics and outcomes were extracted. All analyses were presented with the use of random-effects models. The primary outcome was short-term mortality defined as